EQL Pharma AB (publ) (FRA:7JK)

EQL Pharma AB Statistics

Total Valuation

EQL Pharma AB has a market cap or net worth of EUR 140.69 million. The enterprise value is 174.41 million.

Market Cap	140.69M
Enterprise Value	174.41M

Important Dates

The next estimated earnings date is Tuesday, February 3, 2026.

Earnings Date	Feb 3, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	29.53M
Shares Outstanding	n/a
Shares Change (YoY)	+3.09%
Shares Change (QoQ)	+3.05%
Owned by Insiders (%)	2.31%
Owned by Institutions (%)	11.12%
Float	21.74M

Valuation Ratios

The trailing PE ratio is 52.53 and the forward PE ratio is 32.17.

PE Ratio	52.53
Forward PE	32.17
PS Ratio	3.90
PB Ratio	5.98
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 26.22, with an EV/FCF ratio of -100.49.

EV / Earnings	65.11
EV / Sales	4.80
EV / EBITDA	26.22
EV / EBIT	30.95
EV / FCF	-100.49

Financial Position

The company has a current ratio of 2.03, with a Debt / Equity ratio of 1.72.

Current Ratio	2.03
Quick Ratio	0.98
Debt / Equity	1.72
Debt / EBITDA	6.14
Debt / FCF	-23.37
Interest Coverage	2.59

Financial Efficiency

Return on equity (ROE) is 12.93% and return on invested capital (ROIC) is 7.33%.

Return on Equity (ROE)	12.93%
Return on Assets (ROA)	6.19%
Return on Invested Capital (ROIC)	7.33%
Return on Capital Employed (ROCE)	9.81%
Revenue Per Employee	1.64M
Profits Per Employee	121,751
Employee Count	21
Asset Turnover	0.64
Inventory Turnover	1.36

Taxes

In the past 12 months, EQL Pharma AB has paid 699,185 in taxes.

Income Tax	699,185
Effective Tax Rate	20.70%

Stock Price Statistics

The stock price has decreased by -17.51% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-17.51%
50-Day Moving Average	5.33
200-Day Moving Average	6.95
Relative Strength Index (RSI)	44.80
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EQL Pharma AB had revenue of EUR 36.10 million and earned 2.68 million in profits. Earnings per share was 0.09.

Revenue	36.10M
Gross Profit	14.73M
Operating Income	5.60M
Pretax Income	3.38M
Net Income	2.68M
EBITDA	6.44M
EBIT	5.60M
Earnings Per Share (EPS)	0.09

Balance Sheet

The company has 7.08 million in cash and 40.55 million in debt, giving a net cash position of -33.48 million.

Cash & Cash Equivalents	7.08M
Total Debt	40.55M
Net Cash	-33.48M
Net Cash Per Share	n/a
Equity (Book Value)	23.52M
Book Value Per Share	0.80
Working Capital	18.09M

Cash Flow

In the last 12 months, operating cash flow was -739,978 and capital expenditures -995,502, giving a free cash flow of -1.74 million.

Operating Cash Flow	-739,978
Capital Expenditures	-995,502
Free Cash Flow	-1.74M
FCF Per Share	n/a

Margins

Gross margin is 40.80%, with operating and profit margins of 15.50% and 7.42%.

Gross Margin	40.80%
Operating Margin	15.50%
Pretax Margin	9.36%
Profit Margin	7.42%
EBITDA Margin	17.85%
EBIT Margin	15.50%
FCF Margin	n/a

Dividends & Yields

EQL Pharma AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.09%
Shareholder Yield	-3.09%
Earnings Yield	1.90%
FCF Yield	-1.23%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3